Internal Medicine, Medical Oncology · Houston, TX
NPI
1063676245
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1515 Holcombe Blvd
Houston, TX, 77030
Phone (713) 792-6161
Medicare paid, 2024
$29K
277 services
Medicare patients, 2024
136
Average age 72
Drug cost, 2024
$908K
160 prescriptions
Company payments, 2025
$2,885
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Adi Diab was code 99215 (office e&m - established), 135 times for 80 patients. In total Adi Diab billed 277 services in 13 codes, and Medicare paid $29K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 135 | 80 | $112.52 | $15K |
| 99233 Hospital E&M - Subsequent | Facility | 77 | 26 | $94.23 | $7,256 |
| 99205 Office E&M - New | Facility | 26 | 26 | $135.70 | $3,528 |
By year: 2022 $36K for 350 services; 2023 $31K for 291 services; 2024 $29K for 277 services.
Medicare prescription drug claims, 2024
In 2024, the drug Adi Diab prescribed most often to Medicare patients was Braftovi (Encorafenib), with 28 prescriptions and refills. In total Adi Diab wrote 160 Medicare prescriptions that cost $908K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Braftovi Encorafenib | 28 | 28 | Under 11 | $485K |
| Mektovi Binimetinib | 28 | 28 | Under 11 | $415K |
| Pantoprazole Sodium Generic | 12 | 16 | Under 11 | $75.32 |
| Prednisone Generic | 12 | 12 | 11 | $129 |
Brand drugs: 71 claims; generic drugs: 89 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Adi Diab $2,885 ($2,636 in general payments such as food, travel and fees and $249 for research) from 2 companies. The largest payer was Regeneron Pharmaceuticals, Inc. with $2,885.
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. REGN | 4 | $2,885 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.